5-Amino-1MQ 5-Amino-1-methylquinolinium Not a peptide: a small molecule often looked up alongside peptides Not FDA-approved↗ ↗ No FDA approval reported; studied only in cells and animals April 22, 2026 FDA’s compounding safety-risk page is last updated; it does not list 5-Amino-1MQ. Animal and lab only Abaloparatide Tymlos FDA-approved↗ ↗ As Tymlos for osteoporosis August 17, 2026 DailyMed publishes the Tymlos label version cited on this page. Large human trials Afamelanotide Scenesse FDA-approved↗ ↗ As Scenesse for erythropoietic protoporphyria May 13, 2026 DailyMed publishes the Scenesse label version cited on this page. Smaller human trials Albiglutide Tanzeum FDA-approved↗ As Tanzeum; discontinued April 15, 2014 FDA approves Tanzeum, application 125431, according to Drugs@FDA. Large human trials Amycretin Zenagamtide In clinical trials↗ ↗ Not FDA-approved November 12, 2026 ClinicalTrials.gov first posts AMBITION 1 and AMBITION 2, Phase 3 zenagamtide trials in type 2 diabetes. Smaller human trials AOD-9604 AOD-9604 acetate Not FDA-approved↗ ↗ ↗ FDA advised against adding it to the compounding list April 22, 2026 FDA’s compounding safety-risk page, as last updated, lists AOD-9604 among withdrawn nominations with safety concerns. Limited human data Apraglutide In clinical trials↗ ↗ Not FDA-approved August 4, 2026 ClinicalTrials.gov record NCT07742735 updated Smaller human trials Avexitide In clinical trials↗ ↗ ↗ Not FDA-approved August 24, 2026 ClinicalTrials.gov record NCT06747468 updated Smaller human trials Aviptadil Zyesami In clinical trials↗ ↗ ↗ Not FDA-approved; studied in clinical trials April 22, 2026 FDA’s compounding safety-risk page is last updated; it does not list aviptadil. Large human trials Bivalirudin Angiomax FDA-approved↗ ↗ As Angiomax and generics as an anticoagulant during coronary procedures July 29, 2026 DailyMed publishes the bivalirudin label version cited on this page. Large human trials BPC-157 Body protection compound 157, Bepecin Not FDA-approved↗ October 30, 2026 HHS draft policy: one of six peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement action Limited human data Bremelanotide Vyleesi, PT-141 FDA-approved↗ ↗ As Vyleesi for HSDD in premenopausal women November 9, 2026 U.S. label revised (DailyMed version 2) Large human trials Cagrilintide AM833, CagriSema In clinical trials↗ ↗ ↗ Not FDA-approved October 1, 2026 FDA’s page on unapproved GLP-1 drugs, which says cagrilintide cannot be used in compounding, is updated, as shown by its content-current date. Large human trials Calcitonin salmon Miacalcin, Salmon calcitonin FDA-approved↗ ↗ As Miacalcin for Paget’s disease, high blood calcium and osteoporosis October 29, 2026 Drugs@FDA application ANDA216996 Smaller human trials Carfilzomib Kyprolis FDA-approved↗ ↗ As Kyprolis for relapsed or refractory multiple myeloma July 20, 2026 Drugs@FDA application ANDA209526 Large human trials Cerebrolysin Not a single peptide: a mixture often looked up alongside peptides Not FDA-approved↗ ↗ No FDA approval reported; studied in clinical trials September 29, 2026 ClinicalTrials.gov record NCT07846488 updated Smaller human trials Cetrorelix Cetrotide FDA-approved↗ ↗ As Cetrotide for use in controlled ovarian stimulation April 29, 2026 Drugs@FDA application ANDA218740 Smaller human trials Cibinetide ARA 290 In clinical trials↗ ↗ ↗ Not FDA-approved; studied in clinical trials April 22, 2026 FDA’s compounding safety-risk page is last updated; it does not list cibinetide. Smaller human trials CJC-1295 CJC-1295 DAC Not FDA-approved↗ Named as an unapproved new drug in a federal enforcement case April 22, 2026 FDA’s compounding safety-risk page, as last updated, lists CJC-1295 among withdrawn nominations with safety concerns. Smaller human trials Cotadutide In clinical trials↗ ↗ Not FDA-approved; studied in clinical trials September 3, 2025 ClinicalTrials.gov record NCT05364931 updated Large human trials Dalbavancin Dalvance FDA-approved↗ ↗ As Dalvance for acute bacterial skin infections June 4, 2026 Drugs@FDA application ANDA219604 Large human trials Daptomycin Cubicin, Cubicin RF FDA-approved↗ ↗ As Cubicin RF for skin infections and S. aureus bloodstream infections June 20, 2025 DailyMed publishes the Cubicin RF label version cited on this page. Large human trials Dasiglucagon Zegalogue FDA-approved↗ ↗ As Zegalogue for severe low blood sugar; discontinued June 17, 2026 DailyMed publishes the Zegalogue label version cited on this page. Smaller human trials Degarelix Firmagon FDA-approved↗ ↗ As Firmagon for advanced prostate cancer February 1, 2024 DailyMed publishes the Firmagon label version cited on this page. Large human trials Desmopressin DDAVP FDA-approved↗ ↗ As DDAVP for diabetes insipidus and bedwetting February 27, 2026 Drugs@FDA application ANDA219981 Smaller human trials Difelikefalin Korsuva FDA-approved↗ ↗ As Korsuva for kidney-disease itching in adults on hemodialysis August 31, 2026 Drugs@FDA application ANDA220919 Large human trials Dihexa Dihexa acetate, PNB-0408 Not FDA-approved↗ No FDA approval reported; FDA has no human exposure data for it April 22, 2026 FDA’s compounding safety-risk page, as last updated, lists dihexa acetate among withdrawn nominations. Animal and lab only Dulaglutide Trulicity FDA-approved↗ ↗ As Trulicity August 10, 2026 DailyMed publishes the Trulicity label version cited on this page. Large human trials Efinopegdutide HM12525A, JNJ-64565111 Not FDA-approved↗ ↗ No FDA approval reported; studied in clinical trials September 21, 2026 ClinicalTrials.gov record NCT06465186 updated Smaller human trials Efpeglenatide HM11260C In clinical trials↗ ↗ ↗ Not FDA-approved July 7, 2026 ClinicalTrials.gov record NCT06174779 updated Large human trials Elamipretide SS-31, MTP-131 FDA-approved↗ ↗ As Forzinity under accelerated approval for Barth syndrome July 13, 2026 The 4TAZPower trial record is updated on ClinicalTrials.gov, listing the trial as recruiting. Smaller human trials Eloralintide In clinical trials↗ ↗ Not FDA-approved November 13, 2026 ClinicalTrials.gov record NCT07935304 updated Smaller human trials Emideltide DSIP, Delta sleep-inducing peptide Not FDA-approved↗ Under FDA review for pharmacy compounding July 24, 2026 FDA committee met on seven peptide-related groups of bulk drug substances Smaller human trials Enfuvirtide Fuzeon FDA-approved↗ As Fuzeon for HIV-1; discontinued March 13, 2003 FDA approves Fuzeon, NDA 021481, according to Drugs@FDA. Large human trials Epitalon AEDG, Epithalon Not FDA-approved↗ October 30, 2026 HHS draft policy: one of six peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement action Limited human data Eptifibatide Integrilin FDA-approved↗ ↗ As Integrilin and generics for acute coronary syndrome and PCI May 21, 2026 DailyMed publishes the eptifibatide label version cited on this page. Large human trials Etelcalcetide Parsabiv FDA-approved↗ ↗ As Parsabiv for secondary hyperparathyroidism on hemodialysis March 16, 2026 DailyMed publishes the Parsabiv label version cited on this page. Large human trials Exenatide Byetta, Bydureon FDA-approved↗ ↗ ↗ ↗ ↗ As Byetta, Bydureon and generic exenatide November 13, 2026 FDA publishes its determination that Byetta was not withdrawn from sale for reasons of safety or effectiveness. Large human trials Follistatin-344 FS344 Not a peptide: a protein, larger than a peptide, often looked up alongside peptides Not FDA-approved↗ ↗ No FDA approval reported; studied as a gene therapy in small trials No dated official record yet Limited human data FOXO4-DRI Not FDA-approved↗ ↗ No FDA approval reported; studied only in cells and animals No dated official record yet Animal and lab only Gallium Ga 68 dotatate NETSPOT, Ga-68 DOTATATE FDA-approved↗ ↗ As NETSPOT for PET imaging of neuroendocrine tumors July 7, 2026 DailyMed publishes version 23 of the NETSPOT label, the version cited here. Limited human data Ganirelix Ganirelix acetate FDA-approved↗ ↗ As ganirelix acetate for use in controlled ovarian hyperstimulation October 12, 2026 DailyMed publishes the ganirelix label version cited on this page. Large human trials GHK-Cu Copper tripeptide-1, GHK copper Not FDA-approved↗ Under FDA review for pharmacy compounding by non-injectable routes May 14, 2026 FDA’s 503A list places GHK-Cu, except injectable routes, back under evaluation for pharmacy compounding Smaller human trials GHRP-2 Pralmorelin, Growth hormone-releasing peptide 2 Not FDA-approved↗ No FDA approval reported; on FDA’s compounding safety-risk list (category 2) May 14, 2026 FDA’s 503A nominations list, as last updated, places GHRP-2 in category 3. Smaller human trials GHRP-6 Growth hormone-releasing peptide 6 Not FDA-approved↗ No FDA approval reported; on FDA’s compounding safety-risk list (category 2) April 22, 2026 FDA’s compounding safety-risk page, as last updated, keeps GHRP-6 in category 2. Limited human data Glatiramer acetate Copaxone Not a single peptide: a mixture often looked up alongside peptides FDA-approved↗ ↗ As Copaxone for relapsing multiple sclerosis June 26, 2026 DailyMed publishes version 36 of the Copaxone label, the version cited here. Large human trials Glepaglutide In clinical trials↗ ↗ Not FDA-approved September 29, 2026 ClinicalTrials.gov record NCT07197944 updated Smaller human trials Glucagon Gvoke VialDx, Gvoke FDA-approved↗ ↗ ↗ ↗ As Gvoke, Baqsimi and other glucagon products July 9, 2026 DailyMed publishes the Gvoke and Gvoke VialDx label version cited on this page. Smaller human trials Gonadorelin Factrel, Lutrepulse FDA-approved↗ ↗ As Factrel and Lutrepulse; discontinued October 10, 1989 FDA approves Lutrepulse (gonadorelin acetate), NDA 019687, according to Drugs@FDA. Limited human data Goserelin Zoladex FDA-approved↗ ↗ As Zoladex for prostate cancer, breast cancer and endometriosis March 26, 2026 DailyMed publishes the Zoladex label version cited on this page. Large human trials Hexarelin Examorelin Not FDA-approved↗ ↗ No FDA approval reported April 22, 2026 FDA’s compounding safety-risk page is last updated; it does not list hexarelin. Smaller human trials Histrelin Supprelin LA FDA-approved↗ ↗ As Supprelin LA for central precocious puberty September 29, 2025 DailyMed publishes the Supprelin LA label version cited on this page. Limited human data Humanin Not FDA-approved↗ ↗ No FDA approval reported; studied only in the laboratory No dated official record yet Animal and lab only Icatibant Firazyr FDA-approved↗ ↗ As Firazyr for acute attacks of hereditary angioedema July 17, 2025 DailyMed publishes the Firazyr label version cited on this page. Smaller human trials IGF-1 LR3 Long R3 IGF-I, Long-(Arg3) insulin-like growth factor-I Not a peptide: a protein, larger than a peptide, often looked up alongside peptides Not FDA-approved↗ ↗ No FDA approval reported; studied only in cells and animals No dated official record yet Animal and lab only Insulin glargine-aldy Langlara FDA-approved↗ ↗ ↗ As Langlara October 19, 2026 U.S. label revised (DailyMed version 7) Large human trials Ipamorelin Ipamorelin acetate Not FDA-approved↗ Named as an unapproved new drug in a federal enforcement case April 22, 2026 FDA’s compounding safety-risk page, as last updated, lists ipamorelin acetate in category 2 under the 503B interim policy and among withdrawn nominations. Smaller human trials Kisspeptin-10 Not FDA-approved↗ ↗ ↗ On FDA’s compounding safety-risk list (category 2) October 29, 2024 FDA’s Pharmacy Compounding Advisory Committee votes 11 to 0 against placing kisspeptin-10 on the list. Limited human data KPV Lys-Pro-Val Not FDA-approved↗ October 30, 2026 HHS draft policy: one of six peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement action Animal and lab only Lanreotide Lanreotide acetate, Somatuline Depot FDA-approved↗ ↗ ↗ ↗ As Somatuline Depot and other lanreotide products September 18, 2026 Drugs@FDA application ANDA218217 Smaller human trials Larazotide Larazotide acetate In clinical trials↗ ↗ ↗ Not FDA-approved; studied in clinical trials April 22, 2026 FDA’s compounding safety-risk page is last updated; it does not list larazotide. Large human trials Leuprolide Leuprolide acetate, Lupron FDA-approved↗ ↗ ↗ ↗ ↗ ↗ As Lupron, Eligard, Vobrig and other leuprolide products August 26, 2026 FDA approves Vobrig for central precocious puberty in children. Limited human data Linaclotide Linzess FDA-approved↗ ↗ As Linzess October 19, 2026 U.S. label revised (DailyMed version 40) Large human trials Liraglutide Saxenda, Victoza FDA-approved↗ ↗ ↗ ↗ As Victoza, Saxenda and generic versions July 14, 2026 DailyMed publishes the liraglutide label version cited on this page. Large human trials Lixisenatide Soliqua 100/33, Adlyxin FDA-approved↗ ↗ ↗ As Adlyxin and in Soliqua 100/33 March 20, 2026 DailyMed publishes the Soliqua 100/33 label version cited on this page. Large human trials LL-37 Cathelicidin LL-37, Ropocamptide Not FDA-approved↗ No FDA approval reported; on FDA’s compounding safety-risk list April 22, 2026 FDA’s compounding safety-risk page, as last updated, lists cathelicidin LL-37 among withdrawn nominations with safety concerns. Smaller human trials Lutetium Lu 177 dotatate Lutathera FDA-approved↗ ↗ As Lutathera for gastroenteropancreatic neuroendocrine tumors September 21, 2026 Drugs@FDA application ANDA217060 Smaller human trials Maridebart cafraglutide MariTide, AMG 133 In clinical trials↗ ↗ ↗ Not FDA-approved September 17, 2026 The retained ClinicalTrials.gov record of MARITIME-1 lists the trial as active, not recruiting. Large human trials Mazdutide IBI362, LY3305677 Approval reported abroad↗ ↗ China: approval reported by local government sources October 1, 2026 FDA’s page on unapproved GLP-1 drugs, which names mazdutide, is updated, as shown by its content-current date. Large human trials Mecasermin Increlex Not a peptide: a protein, larger than a peptide, often looked up alongside peptides FDA-approved↗ ↗ As Increlex for severe primary IGF-1 deficiency in children November 17, 2025 DailyMed publishes version 4 of the Increlex label, the version cited here. Limited human data Melanotan II Not FDA-approved↗ No FDA approval reported; on FDA’s compounding safety-risk list April 22, 2026 FDA’s compounding safety-risk page, as last updated, lists Melanotan II among withdrawn nominations with safety concerns. Smaller human trials Metreleptin Myalept Not a peptide: a protein, larger than a peptide, often looked up alongside peptides FDA-approved↗ ↗ As Myalept for generalized lipodystrophy March 10, 2025 DailyMed publishes version 18 of the Myalept label, the version cited here. Limited human data MK-677 Ibutamoren, Ibutamoren mesylate Not a peptide: a small molecule often looked up alongside peptides Not FDA-approved↗ ↗ No FDA approval reported; on FDA’s compounding safety-risk list (category 2) October 29, 2024 FDA’s Pharmacy Compounding Advisory Committee votes 13 to 1 against placing ibutamoren mesylate on the 503A bulks list. Large human trials Motixafortide Aphexda FDA-approved↗ ↗ As Aphexda for stem cell mobilization in multiple myeloma October 19, 2026 DailyMed publishes the Aphexda label version cited on this page. Smaller human trials MOTS-c MOTS-C, Mitochondrial open reading frame of the 12S rRNA-c Not FDA-approved↗ October 30, 2026 HHS draft policy: one of six peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement action Animal and lab only Nafarelin Synarel FDA-approved↗ ↗ As Synarel for central precocious puberty and endometriosis March 10, 2026 DailyMed publishes the Synarel label version cited on this page. Smaller human trials Nesiritide Natrecor Not FDA-approved↗ ↗ FDA approval withdrawn in 2020 after the product left the market June 15, 2020 FDA’s withdrawal of Natrecor’s approval takes effect, according to its May 14, 2020 Federal Register notice. Large human trials Octreotide Octreotide acetate, Sandostatin FDA-approved↗ ↗ ↗ ↗ ↗ As Sandostatin and other octreotide products May 13, 2026 FDA recall report D-0519-2026 Smaller human trials Orforglipron Foundayo Not a peptide: a small molecule often looked up alongside peptides FDA-approved↗ ↗ As Foundayo for weight reduction in adults August 13, 2026 DailyMed publishes version 10 of the Foundayo label, the version cited here. Large human trials Oxytocin Pitocin FDA-approved↗ ↗ As Pitocin for labor and bleeding after birth May 21, 2026 DailyMed publishes the Pitocin label version cited on this page. Large human trials Palopegteriparatide Yorvipath FDA-approved↗ ↗ As Yorvipath for hypoparathyroidism in adults November 9, 2026 DailyMed publishes the Yorvipath label version cited on this page. Smaller human trials Pasireotide Signifor FDA-approved↗ ↗ As Signifor for Cushing’s disease February 18, 2026 DailyMed publishes the Signifor label version cited on this page. Smaller human trials PEG-MGF Mechano growth factor pegylated, Mechano growth factor Not FDA-approved↗ ↗ No FDA approval reported; FDA has no human exposure data for it May 14, 2026 FDA’s updated 503A category lists keep mechano growth factor in category 3. Animal and lab only Pegcetacoplan Empaveli, Syfovre FDA-approved↗ ↗ As Empaveli for PNH and two complement-driven kidney diseases August 25, 2026 DailyMed publishes the Empaveli label version cited on this page. Smaller human trials Peginesatide Omontys, Peginesatide acetate Not FDA-approved↗ ↗ FDA approval withdrawn in 2019 at the company’s request, after a 2013 recall February 13, 2019 FDA’s withdrawal of approval of NDA 202799 takes effect, at the company’s request. Large human trials Pemvidutide ALT-801 In clinical trials↗ ↗ Not FDA-approved August 31, 2026 The retained ClinicalTrials.gov record of a Phase 3 trial in MASH lists it as recruiting. Smaller human trials Petrelintide ZP8396 In clinical trials↗ ↗ ↗ Not FDA-approved November 5, 2026 The retained ClinicalTrials.gov records of ZUPREME-4 and a third Phase 3 trial list them as recruiting. Large human trials Plecanatide Trulance FDA-approved↗ ↗ As Trulance April 5, 2024 DailyMed publishes the Trulance label version cited on this page. Large human trials Pramlintide SymlinPen, Symlin FDA-approved↗ ↗ As Symlin August 20, 2024 DailyMed publishes the Symlin label version cited on this page. Large human trials Retatrutide LY3437943 In clinical trials↗ ↗ ↗ Not FDA-approved October 1, 2026 FDA’s page on unapproved GLP-1 drugs, which says retatrutide cannot be used in compounding, is updated, as shown by its content-current date. Large human trials Rusfertide Mimrylo FDA-approved↗ ↗ As Mimrylo for erythrocytosis in polycythemia vera November 11, 2026 DailyMed publishes the Mimrylo label version cited on this page. Smaller human trials Secretin ChiRhoStim, Human secretin FDA-approved↗ ↗ As ChiRhoStim for pancreatic and gastrinoma testing November 17, 2025 DailyMed publishes the ChiRhoStim label version cited on this page. Smaller human trials Selank Selank acetate Not FDA-approved↗ No FDA approval reported; FDA lists safety concerns from a withdrawn compounding nomination April 22, 2026 FDA’s compounding safety-risk page, as last updated, lists selank acetate among withdrawn nominations with possible safety risks. Limited human data Semaglutide Wegovy, Ozempic FDA-approved↗ ↗ ↗ ↗ As Ozempic, Rybelsus and Wegovy October 1, 2026 FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date. Large human trials Semax Not FDA-approved↗ October 30, 2026 HHS draft policy: one of six peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement action Limited human data Sermorelin Geref Not FDA-approved↗ ↗ FDA approval withdrawn in 2009 at the maker’s request, not for safety or effectiveness March 4, 2013 FDA publishes its determination that Geref was not withdrawn from sale for reasons of safety or effectiveness. Limited human data Setmelanotide Imcivree FDA-approved↗ ↗ As Imcivree for specific rare causes of obesity April 2, 2026 DailyMed publishes the Imcivree label version cited on this page. Smaller human trials SLU-PP-332 Not a peptide: a small molecule often looked up alongside peptides Not FDA-approved↗ ↗ No FDA approval reported; studied only in cells and animals No dated official record yet Animal and lab only Survodutide BI 456906 In clinical trials↗ ↗ ↗ Not FDA-approved October 1, 2026 FDA’s page on unapproved GLP-1 drugs, which names survodutide among drugs sold with false research-use labels, is updated, as shown by its content-current date. Large human trials TB-500 N-terminal acetylated 17-23 fragment of thymosin beta-4 Not FDA-approved↗ October 30, 2026 HHS draft policy: one of six peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement action Animal and lab only Teduglutide Gattex FDA-approved↗ ↗ As Gattex for short bowel syndrome September 18, 2025 DailyMed publishes the Gattex label version cited on this page. Smaller human trials Teriparatide Forteo FDA-approved↗ ↗ ↗ ↗ ↗ ↗ As Forteo and other teriparatide products October 23, 2026 FDA approves another generic teriparatide application (ANDA214412), according to Drugs@FDA. Large human trials Terlipressin Terlivaz FDA-approved↗ ↗ As Terlivaz for hepatorenal syndrome October 26, 2026 DailyMed publishes the Terlivaz label version cited on this page. Large human trials Tesamorelin Egrifta FDA-approved↗ ↗ As Egrifta for HIV-associated abdominal fat July 31, 2026 DailyMed publishes the Egrifta SV label version cited on this page. Large human trials Tesofensine NS2330 Not a peptide: a small molecule often looked up alongside peptides Not FDA-approved↗ ↗ No FDA approval reported; studied in clinical trials February 26, 2024 ClinicalTrials.gov record NCT03149445 updated Smaller human trials Thymopentin Timunox Not FDA-approved↗ ↗ No FDA approval reported; studied in clinical trials June 24, 2005 ClinicalTrials.gov record NCT00002049 updated Large human trials Thymosin alpha-1 Thymalfasin Not FDA-approved↗ ↗ ↗ FDA advised against adding it to the compounding list April 22, 2026 FDA’s compounding safety-risk page, as last updated, lists thymosin alpha-1 among withdrawn nominations with safety concerns. Smaller human trials Thymosin beta-4 Not FDA-approved↗ ↗ No FDA approval reported April 22, 2026 FDA’s compounding safety-risk page, as last updated, lists the TB-500 fragment but not thymosin beta-4 itself. Smaller human trials Tirzepatide Zepbound, Mounjaro FDA-approved↗ ↗ ↗ As Mounjaro and Zepbound October 1, 2026 FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date. Large human trials Triptorelin Trelstar FDA-approved↗ ↗ As Trelstar for advanced prostate cancer July 10, 2026 DailyMed publishes the Trelstar label version cited on this page. Large human trials Trofinetide Daybue FDA-approved↗ ↗ As Daybue for Rett syndrome September 11, 2026 DailyMed publishes the Daybue label version cited on this page. Smaller human trials Vasopressin Vasostrict FDA-approved↗ ↗ As Vasostrict for vasodilatory shock May 18, 2026 DailyMed publishes the Vasostrict label version cited on this page. Limited human data VK2735 In clinical trials↗ ↗ ↗ Not FDA-approved November 16, 2026 ClinicalTrials.gov record NCT07868835 updated Smaller human trials Vosoritide Voxzogo FDA-approved↗ ↗ As Voxzogo under accelerated approval for achondroplasia November 26, 2025 DailyMed publishes the Voxzogo label version cited on this page. Smaller human trials Ziconotide Prialt FDA-approved↗ ↗ As Prialt for severe chronic pain July 14, 2025 DailyMed publishes the Prialt label version cited on this page. Smaller human trials Zilucoplan Zilbrysq FDA-approved↗ ↗ As Zilbrysq for generalized myasthenia gravis February 5, 2026 DailyMed publishes the Zilbrysq label version cited on this page. Smaller human trials